Why is Parmax Pharma falling/rising?

As of 14-Aug, Parmax Pharma Ltd's stock price is currently at Rs 38.54, reflecting an increase of Rs 2.54 or 7.06%. The stock has shown a strong performance today, outperforming its sector by 6.94%. Despite this positive movement, the stock has faced challenges in the longer term, with a year-to-date decline of 12.90% and a negative book value indicating weak long-term fundamental strength. The company's net sales have decreased significantly by 43.96% in the latest six months, and its ability to service debt is concerning, as evidenced by a poor EBIT to interest ratio of 0.66. Additionally, the stock's delivery volume has fallen sharply, indicating declining investor participation.
In the broader market context, Parmax Pharma's short-term performance has been notably better than the benchmark, with a 1-week return of 8.87% compared to a slight decline of 0.03% in the Sensex. However, over the past month, the stock has underperformed with a decline of 1.33%, while the benchmark fell by 2.01%. This suggests that, despite recent gains, the stock's overall trajectory remains uncertain due to its weak financial fundamentals and declining sales, which could impact investor sentiment moving forward.